TRINITY BIOTECH PLC

TRINITY BIOTECH PLC is a biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. Following the acquisition of the biosensor assets of Waveform Technologies Inc. in 2024, the company has been developing a range of biosensor devices and related services, starting with a continuous glucose monitoring (CGM) product. Through its subsidiaries, TRINITY BIOTECH PLC develops, acquires, manufactures, and markets medical diagnostic products for both the clinical laboratory and point-of-care segments of the diagnostic market. The company's products are used to detect autoimmune, infectious, and sexually transmitted diseases, disorders of the liver and intestine, and to monitor markers for diabetes. TRINITY BIOTECH PLC markets its portfolio of several hundred products to customers in approximately 100 countries globally. This is achieved through its own sales force and a network of international distributors and strategic partners. Key subsidiaries involved in research and development, manufacturing, and marketing include Trinity Biotech Manufacturing Limited, Konamite Limited, and EpiCapture Limited, all based in Bray, Ireland; Clark Laboratories Inc, Biopool US Inc (trading as Trinity Biotech USA), and Immco Diagnostics Inc in the United States; Primus Corporation in Kansas City; Trib Biosensors Inc in Wilsonville, Oregon; Nova Century Scientific Inc in Burlington, Canada; Trinity Biotech Brazil in Sao Paulo, Brazil; and Metabolomic Diagnostics Limited in Cork, Ireland. Principal product brand names include UniGold, MarDx, Premier, ImmuBlot, EZ Captia, TrinScreen, FlexTrans, Ultra, ImmuGlo, ImmuLisa, and OTOblot. The company sells products through direct sales organizations in the United States, Brazil, and to an extent in the United Kingdom, France, and Germany, and through a network of principal distributors and non-governmental bodies into approximately 100 countries worldwide.